Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses

Ashkan Rezazadeh Ardabili^{1

2}, Adriaan A Van Bodegraven^{1

3}

Affiliations

¹ Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
² School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Centre+, Maastricht, the Netherlands.
³ Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen, the Netherlands.

Editorial

Ashkan Rezazadeh Ardabili et al. Aliment Pharmacol Ther. 2023 Oct.

. 2023 Oct;58(8):832-833.

doi: 10.1111/apt.17683.

Ashkan Rezazadeh Ardabili^{1

2}, Adriaan A Van Bodegraven^{1

3}

¹ Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
² School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Centre+, Maastricht, the Netherlands.
³ Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen, the Netherlands.

No abstract available

Comment on

Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
Everhov ÅH, Söderling J, Befrits G, Khalili H, Bröms G, Neovius M; SWIBREG study group; Askling J, Halfvarson J, Ludvigsson JF, Olén O. Everhov ÅH, et al. Aliment Pharmacol Ther. 2023 Oct;58(7):692-703. doi: 10.1111/apt.17675. Epub 2023 Aug 18. Aliment Pharmacol Ther. 2023. PMID: 37594381

1. Everhov Å, Söderling J Befrits G, Khalili H, Bröms G, Neovius M, Olén O, et al. Increasing healthcare costs in inflammatory bowel disease 2007 to 2020 in Sweden. Aliment Pharmacol Ther. 2023;58:692-703.
1. WHO. https://www.who.int/data/nutrition/nlis/info/health-expenditure
1. Burisch J, Zhao M, Odes S, de Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8(5):458-492.
1. The Lancet Gastroenterology Hepatology. The economic burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2023;8(5):391.
1. Selinger CP. Biologicals are the main contributor to cost of care for IBD: a European perspective. Lancet Gastroenterol Hepatol. 2020;5(5):421-422.